Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer
Pathological tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer作者机构:General Visceral and Transplantation Surgery University Hospital of Mainz
出 版 物:《Hepatobiliary & Pancreatic Diseases International》 (国际肝胆胰疾病杂志(英文版))
年 卷 期:2019年第18卷第4期
页 面:305-306页
核心收录:
学科分类:1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
主 题:Surgery mortality operative
摘 要:Surgery is the standard therapy for pancreatic ductal adenocarcinoma(PDAC).After the dramatic decline of operative mortality over the past decades,the indications for pancreas resections have been continuously extended:currently resections of the portal/superior mesenteric vein are considered standard by many centers,and even arterial resections are under *** these changes,different expert groups have defined resectability criteria containing a grey zone(“borderline resectable disease)of tumors,which may be technically resectable with appropriate surgical expertise,but resection inherits an increased risk of an R1-resection[1].